In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors by Berthon, Céline et al.
ORIGINAL ARTICLE
In acute myeloid leukemia, B7-H1 (PD-L1) protection
of blasts from cytotoxic T cells is induced by TLR ligands
and interferon-gamma and can be reversed using MEK inhibitors
Ce ´line Berthon • Virginie Driss • Jizhong Liu •
Klaudia Kuranda • Xavier Leleu • Nathalie Jouy •
Dominique Hetuin • Bruno Quesnel
Received: 3 November 2009/Accepted: 16 August 2010/Published online: 4 September 2010
 The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract B7-H1 (PD-L1) is a B7-related protein that
inhibits T-cell responses. B7-H1 participates in the immu-
noescape of cancer cells and is also involved in the long-
term persistence of leukemic cells in a mouse model of
leukemia. B7-H1 can be constitutively expressed by cancer
cells, but is also induced by various stimuli. Therefore, we
examined the constitutive and inducible expression of B7-
H1 and the consequences of this expression in human acute
myeloid leukemia (AML). We analyzed B7-H1 expression
in a cohort of 79 patients with AML. In addition, we studied
blast cells after incubation with interferon-gamma or toll-
like receptors (TLR) ligands. Finally, we evaluated func-
tionality of cytotoxic T-cell activity against blast cells.
Expression of B7-H1 upon diagnosis was high in 18% of
patients. Expression of TLR2, 4 and 9 was detected in one-
third of AML samples. Expression of TLR2 and TLR4
ligands or IFN-c induced by B7-H1 was found to protect
AML cells from CTL-mediated lysis. Spontaneous B7-H1
expression was also found to be enhanced upon relapse in
some patients. MEK inhibitors, including UO126 and
AZD6244, reduced B7-H1 expression and restored CTL-
mediated lysis of blast cells. In AML, B7-H1 expression by
blasts represents a possible immune escape mechanism. The
inducibility of B7-H1 expression by IFN-c or TLR ligands
suggests that various stimuli, either produced during the
immune response against leukemia cells or released by
infectious microorganisms, could protect leukemic cells
from T cells. The efﬁcacy of MEK inhibitors against B7-
H1-mediated inhibition of CTLs suggests a possible cancer
immunotherapy strategy using targeted drugs.
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Introduction
Blast cells found in acute myeloid leukemia (AML) can
grow in patients despite an autologous immune response.
Numerous leukemia-associated antigens have been descri-
bed, and cytotoxic T cells against these antigens have been
detected [1]. However, leukemia cells may escape auto-
logous or allogenic immune responses through various
mechanisms, such as indoleamine 2, 3 dioxygenase activity
in blast cells, production of inhibitory cytokines, or active
suppression of NK cells and dendritic cells [2, 3].
In AML, B7-H1 is a candidate molecule for inhibition of
T cells. In a mouse model of AML, expression of B7-H1
allowed dormant tumor cells to escape from CTLs [4–6][ 7,
8]. B7-H1 (also known as PD-L1 or CD274) is a B7 family
member, and it is a ligand for PD-1 (programmed death-1,
a member of the CD28 family) and B7.1 [9–12]. B7-H1 is
broadly distributed in various tissues and cell types and is
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DOI 10.1007/s00262-010-0909-yoften expressed following exposure to inﬂammatory cyto-
kines, especially IFN-c. B7-H1 can inhibit T-cell activation
and CTL-mediated lysis. Various human carcinomas
express B7-H1. We recently showed that malignant plasma
cells from most multiple myeloma (MM) patients also
express B7-H1, and expression is enhanced by IFN-c- and
toll-like receptor (TLR) stimulation via a MEK/ERK- and
MyD88/TRAF6-dependent pathway [13]. This induced
expression can inhibit T-cell responses, indicating B7-H1
expression as a possible immune evasion mechanism in
MM. Thus, the immune response against tumor cells via
IFN-c release or stimulation of TLR by pathogen-associ-
ated molecular patterns (PAMP) released by microorgan-
isms may actually promote tumor growth by inducing
B7-H1 expression, which then inhibits CTLs.
If blast cells in human AML are also able to spontane-
ously express B7-H1 spontaneously or upon stimulation,
they would escape from the autologous immune response
and from the graft-versus-leukemia effect after allogenic
stem cell transplantation. To investigate whether B7-H1
may play such a role in human leukemia, we analyzed blast
cells from a cohort of patients with AML. We studied
spontaneous B7-H1 expression and expression after stim-
ulation by TLR ligands or IFN-c. Here, we show that B7-
H1 expression in AML cells is mostly inducible via TLR
stimulation and IFN-c may appear upon relapse, thus pro-
tecting blast cells from CTLs. MEK inhibitors are able to
inhibit B7-H1 expression and restore sensitivity of blast
cells to CTL, thereby offering new opportunities to develop
immunotherapy strategies via small, targeted molecules.
Materials and methods
Patients and cell lines
Bone marrow mononuclear cells from 79 patients with
AML were isolated by Ficoll–Hypaque centrifugation after
the donors had given informed consent in accordance with
the Declaration of Helsinki. This study was approved
by the Institutional Review Board of Tumorotheque/CHU
Lille. Patient characteristics are listed in Table 1.
K562, U937, HL60, THP-1, KG1a, Jurkat, Raji, WEHI-
3b (all purchased from ATCC) and DA1-3b cell lines were
cultured in RPMI 1640 supplemented with 10% fetal calf
serum, L-glutamine, 100 U/ml penicillin and 100 lg/ml
streptomycinat37Cin5%CO 2.EstablishmentoftheDA1-
3bBCR/ABLcelllinehasbeendescribedpreviously[8,14].
Flow cytometry and Western blot analyses
Expression of B7 family molecules and TLR was evaluated
by ﬂow cytometry in blast cells gated with anti-CD45-PC5
(clone J33; Beckman Coulter, Miami, FL) monoclonal
antibody (mAb). The following mAbs were used: anti-
CD80-FITC (clone L307.4), anti-CD86-FITC (clone 2331),
anti-B7-H1-PE (clone MIH1), anti-B7-DC-PE (clone
MIH18), anti-B7-H4-PE (clone 7H3.1), anti-TLR2-FITC
(clone TL2.1), anti-TLR 4-PE (HTA 125), anti-TLR9-PE
(eBiosciences, San Diego, CA) and appropriate isotype
controls with prior incubation with Fc-block reagent
(Miltenyi Biotec, Bergisch Gladbach, Germany). In some
experiments, B7-H1 expression was also evaluated by
Western blot using the anti-human B7-H1 antibody (clone
130002) or anti-mouse B7-H1 mAb (clone 179711) (R&D
Systems, Minneapolis, MN).
Quantitative real-time PCR
Total RNA was extracted from cell lines and blast cells
using conventional techniques. Levels of B7-H1 mRNA
expression were measured using the forward primer
(50-AGG AGA TTA GAT CCT GAG GAA AAC C-30),
reverse primer (50-GGA CTC ACT TGG TAA TTC TGG
GA) and TaqMan probe (50FAM-CTG GCA CAT CCT
C–30MGB), with the TaqMan Universal Master Mix
(Applied Biosystems, Foster City, CA). Real-time PCR was
performed with an ABI PRISM 7700HT sequence detection
Table 1 Patient characteristics
Total number of patients 79
Sex ratio 0.95
Median age (range) 59 (23–89)
FAB
M0 8
M1 9
M2 24
M3 1
M4 14
M5 11
M6 2
AML evolved from MDS 10
Karyotype
Good 4
Intermediate 39
Poor risk 18
Failed 18
Gene mutations
NPM1 14
CEBPA 3
FLT3-ITD 12
FLT3 m 3
WT1 3
MLL 2
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123system. A twofold serial dilution of cDNA from a lung car-
cinoma cell line (A549) was used to generate a standard
curve. A negative control containing no RNA template was
used in each run. 18S ribosomal RNA (PDAR 18S; Applied
Biosystems) was ampliﬁed as an internal control. An equal
quantity of cDNA prepared from 10 ng of RNA was loaded
forPCRreaction.Resultsweremeasuredviastandardcurves
and expressed as ratios.
Cytokines, TLR ligands and signal transduction
experiments
To explore signals that induced B7-H1 expression, the
following cytokines and reagents were used: AG490 JAK2
inhibitor (25 lM), PD98059 MEK1 inhibitor (25 lM),
SB203580 p38MAPK inhibitor (3 lM), LY294002 PI-3K
inhibitor (25 lM), rapamycin mTOR inhibitor (10 nM),
1L6hydroxymethyl-chiro-inositol-2-R-2-O-methyl-3-
O-octadecyl-sn-glycerocarbonate AKT inhibitor (10 lM)
(all from Calbiochem, San Diego, CA); SP600125 JNK
inhibitor (25 lM; Biosource, Camarillo, CA), U0126
MEK1/2 inhibitor (20 lM; Cell Signaling Technology,
Danvers, MA), AZD6244 MEK1/2 inhibitor (1 lM; kindly
provided by Astra Zeneca), recombinant human IFN-c
(500 IU/ml; PeproTech, Rocky Hill, NJ), peptidoglycan
TLR2 ligand (PGN, 2.5 lg/ml, from S. aureus), CpG oligo-
nucleotide TLR9 ligand (type C, ODN M362, 5 lM) and
its control CpG DNA, and TLR4 ligand Ultrapure lipo-
polysaccharide(500 ng/mlLPS,fromE.colistrainO111:B4)
(from InvivoGen/Cayla, Toulouse, France).
Generation of cytotoxic T cells
T cells from the peripheral blood of a healthy donor were
isolated using a Pan T Cell Isolation Kit (Miltenyi Biotec)
and cultured in RPMI 1640 (Life Technologies) supple-
mented with 10% fetal calf serum, 100 IU/ml penicillin,
100 mg/ml streptomycin, 2 mM L-glutamine, 50 lM
b-mercaptoethanol and 20 IU/ml interleukin 2 (PeproTech,
Rocky Hill, USA). The culture medium was changed every
2 days, and irradiated AML cells (1/1 ratio) were added
once a week [15]. After 15 days, dead cells were removed
and CD8a
? cells were puriﬁed using a CD8a
? T-cell Iso-
lation Kit (Miltenyi Biotec). CTL activity was assessed
with the Cytotox Non-Radioactive 96 kit (Promega, Mad-
ison, WI) using freshly thawed AML blasts as targets. To
block B7-H1, target cells were pre-incubated with B7-H1
blocking antibodies (clone MIH1; eBiosciences) at 2 lg/ml
2 h before the CTL assay. The speciﬁcity of CTL-mediated
lysis of AML cells was veriﬁed with HEK-293 cells as
targets. MHC class I-restricted lysis was veriﬁed with an
anti-HLA-ABC (clone W6/32; eBiosciences) or isotype
control. The absence of NK cell-mediated cytotoxicity was
veriﬁed with K562 cells as targets.
Statistical analyses
Statistical analyses were performed with the Sigma Stat
3.11 software (SPSS Sciences, Chicago, IL).
Results
Expression of B7-H1 in leukemic cell lines
B7-H1 expression is reported to be high in several human
cancers; however, its expression in human cancer cell lines
has appeared to be modest. We looked at B7-H1 expression
in several myeloid lines (U937, K562, KG1a, HL60,
THP-1) and lymphoid lines (Raji, Jurkat). Under basal
conditions, only THP-1 and LAMA-84 showed substantial
expression of B7-H1 (Fig. 1a). Its expression increased
after a 24-h incubation of THP-1 and LAMA-84 cells in
500 IU/ml IFN-c. Expression also increased in U937 and
Jurkat cells on 24-h incubation in 500 IU/ml IFN-c, sug-
gesting that leukemic cells could express B7-H1 under
appropriate conditions.
Expression of B7 family molecules in blast cells
from AML
These results prompted us to study B7 family molecules in
blasts from a large cohort of AML patients under basal
conditions or after stimulation. On diagnosis, spontaneous
expression of B7-H1 was detected in[30% of blast cells in
18% of patients. No correlations with age, FAB type,
karyotype, leukocyte count or NPM, FLT3, MLL, CEBPA
or WT1 mutations were found upon diagnosis. B7-DC,
another PD-1 ligand (PD-1 is the B7-H1 receptor), was not
detected. B7-H4, currently the only other known immu-
nosuppressive B7 molecule [10, 12], was also absent
(Fig. 1b). According to previous reports [16–18], B7.2
expression is high in most patients, and B7.1 expression
resembles that of B7-H1.
As B7-H1 is usually inducible in normal cells, we
investigated whether several stimuli known to play a role in
the immune response could induce expression. TLR2,
TLR4 and TLR9, which induce B7-H1 in MM [13], were
expressed in 29, 27 and 36% of AML samples, respectively
(Fig. 1c). No correlation between TLR expression and
AML characteristics was observed. IFN-c signiﬁcantly
enhanced B7-H1 expression (Fig. 1d). PGN and LPS, the
TLR2 and TLR4 ligands, respectively, also induced
B7-H1. However, ODN, the TLR9 ligand, had no effect on
B7-H1 expression. Signiﬁcant positive correlations were
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123Fig. 1 B7-H1 and TLR
expression in leukemic cell lines
and blast cells from AML.
a Flow cytometry analysis of
B7-H1 expression in myeloid
leukemic cell lines (LAMA-84,
HL60, K562, U937, KG1a,
THP-1) and lymphoid lines
(Raji, Jurkat) with or without
incubation with 500 IU/ml
IFN-c for 24 h. Data represent
the mean and SD of three
experiments. b B7-H1, B7-DC,
B7.1, B7.2 and B7-H4
expression measured by ﬂow
cytometry in 79 blast samples
from AML patients collected at
the time of diagnosis. c Same as
in (b), but this is for TLR2,
TLR4 and TLR9 expression.
d B7-H1 expression in 60 blast
samples collected upon
diagnosis with or without
incubation with either
500 IU/mL IFN-c or TLR
ligands (500 ng/ml LPS,
2.5 lg/ml PGN or 5 lM ODN)
for 24 h. *P\1 9 10
-6,
**P\1 9 10
-5,
***P\6 9 10
-5, paired t test.
e Correlation between TLR2 or
TLR4 expression and percent of
B7-H1-positive cells (Pearson’s
correlation)
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123found between LPS-induced B7-H1 expression and TLR4
(r = 0.41, p = 0.01, Pearson’s correlation) and between
PGN-induced expression and TLR2 (r = 0.51, p = 0.01),
but not between ODN and TLR9 (r = 0.1, p = 0.5)
(Fig. 1e). A signiﬁcant correlation between PGN- and
LPS-induced B7-H1 expression (r = 0.9, p = 0.001,
Supplementary Figure S1a) and between IFNc- and PGN-
or LPS-induced B7-H1 expression (r = 0.8, p = 0.01,
Supplementary Figure S1c,d) was also observed, indicating
that in most samples B7-H1 expression was inducible
through different stimuli. Correlation between TRL2 and
TLR4 expression was signiﬁcant, but less pronounced
(r = 0.75, p = 0.01, Supplementary Figure S1b). These
data suggest that blast cells that are refractory to stimula-
tion with one B7-H1-inducing ligand are usually refractory
to others. However, we cannot rule out that TLR ligands
may induce B7-H1 in some patients via receptors other
than TLRs.
Enhanced B7-H1 expression upon relapse
In a mouse model of tumor dormancy, enhanced B7-H1
expression in dormant tumor cells enables long-term per-
sistence of these cells through inhibition of CTL-mediated
killing [4–6]. In humans in complete remission, dormant
leukemia cells cannot be obtained for study, so we can only
speculate about the mechanisms that permit these cells to
persist. In ﬁve out of nine patients with AML, spontaneous
B7-H1 expression (p = 0.041, paired t test) and expression
after IFN-c exposure (p = 0.038) increased at relapse
(Fig. 2a–c). Thus, some patients may show increased B7-
H1 expression upon relapse. However, we could not
determine whether this increase was acquired during the
period of complete remission or upon relapse, and the low
number of patients analyzed in this study requires cautious
interpretation of these ﬁndings.
B7-H1-mediated resistance to CTLs is induced
by TLR stimulation
B7-H1 is a known inhibitor of T-cell functions, including
CTL-mediated lysis. To evaluate the signiﬁcance of B7-H1
expression in blast cells, we tested six blast samples with
allogenic CTLs (Fig. 3a). Under basal conditions, blocking
B7-H1 with a speciﬁc antibody had little effect on CTL
lysis. However, when blast cells were pre-incubated for
24 h with LPS, they demonstrated a higher resistance to
CTL-mediated killing. However, this protection was par-
tially abolished when anti-B7-H1 was added to the med-
ium. Thus, in AML, stimulation of TLRs in blast cells
protects them from CTL killing via B7-H1 overexpression.
The differential expression of B7-H1 between the time
of diagnosis and relapse seen in some patients may also
have a functional consequence. Blasts from a patient during
AML relapse were more resistant to CTL-mediated killing
than blasts isolated upon diagnosis, and this difference was
reversible by incubation with an anti-B7-H1 antibody
(Fig. 3b).
Blocking MEK but not PI3K/mTOR decreases B7-H1
expression
In MM, B7-H1 expression is activated by IFN-c and TLR
ligands via a common signaling pathway involving
MyD88/MEK/ERK/STAT1, which activates transcription
[13]. We conﬁrmed that in the AML cell lines THP-1
and U937, blocking MEK inhibits B7-H1 transcription
(Fig. 4a). B7-H1 protein expression was measured by
Western blot because the autoﬂuorescence of leukemic
cells treated with UO126 made comparison between dif-
ferent MEK inhibitors difﬁcult by ﬂow cytometry. Blast
cells from patients with AML and a mouse leukemia cell
line showed reduced B7-H1 protein expression after
exposure to MEK inhibitors, conﬁrming that MEK is an
important regulator of B7-H1 expression in leukemic cells
(Fig. 5). Interestingly, inhibition was found with UO126
and with AZD6244, which is an MEK inhibitor that is
currently under clinical development for the treatment of
various types of tumors. Previous reports proposed that
PI3K/AKT may also enhance expression of B7-H1 [19].
Surprisingly, blocking PI3K/mTOR with LY294002 or
blocking mTORC1 with rapamycin slightly enhanced B7-
H1 expression in human and mouse leukemic cell lines that
were either untreated or exposed to IFN-c (Figs. 4a, 5).
This result was also found, but to a lesser degree, in human
AML blasts treated with LY294002. However, rapamycin
(Fig. 4b, c) and the AKT inhibitor (data not shown) had no
signiﬁcant effect on B7-H1 expression. Thus, in AML,
clinical targeting of the PI3K/AKT/mTOR pathway may
not actually inhibit B7-H1 expression.
MEK inhibitors enhance CTL-mediated lysis
of blast cells
As MEK inhibitors are able to inhibit B7-H1 expression,
we tested the effect of the MEK inhibitors, UO126 and
AZD6244, on the sensitivity of blast cells from ten patients
with AML to allogenic CTL-mediated lysis (Fig. 6a, d).
B7-H1 expression was inducible with LPS in seven of the
ten tested samples and was signiﬁcantly reduced by the
MEK inhibitor, AZD6244 (Fig. 6b, c). Pre-incubation of
these B7-H1-inducible leukemic cells with UO126 resulted
in increased cytotoxicity. Furthermore, pre-incubation with
AZD6244 also resulted in increased cytotoxicity, but to a
lesser degree at the doses selected (Fig. 6a). The three
patients who did not express B7-H1 after LPS treatment
Cancer Immunol Immunother (2010) 59:1839–1849 1843
123showed no improvement in cytotoxicity upon treatment
with AZD6244 or UO126 (Fig. 6d).
Discussion
AML blasts are known to be immunosuppressive, but the
precise nature of the signals produced by these cells to
inhibit T-cell function remains elusive [20–22]. B7 family
molecules may be responsible for this immunosuppressive
effect. B7.1 and B7.2, which both activate T cells via
binding to CD28 and suppress T cells via CTLA-4, are
expressed by leukemic cells [17, 18]. Furthermore, both
ligands activate or inhibit T cells in AML, depending on
their level of expression, which can be modiﬁed in vitro
and in vivo by chemotherapy [18]. Other more recently
Fig. 2 B7-H1 at relapse.
a Histograms of B7-H1 ﬂow
cytometric analysis of blast cells
collected from a patient with
AML at the time of diagnosis
and relapse. Thick line anti-B7-
H1 mAb. Thin line control
isotype. b B7-H1 expression
upon diagnosis and relapse in
nine AML samples. c Same
patients as in (b), but cells were
incubated for 24 h with
500 IU/mL IFN-c
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123described members of the B7 family have not been
investigated as thoroughly. B7-H2, which interacts with
ICOS on activated T cells, is expressed on AML cells and
induces CD4? proliferation as well as IL4 and IL10 pro-
duction [16]. B7-H1 may suppress T-cell function through
its receptor, PD-1, and possibly through direct interaction
with B7.1 [23].
Marked expression of B7-H1 has been reported in sev-
eral human and mouse tumors [13, 24, 25]. However,
reports on AML are conﬂicting. Tamura et al. detected B7-
H1 expression only in a minority of 69 de novo AML cases
[16]. Another study reported signiﬁcant expression in 17 of
30 cases of leukemia of various types [26], although inhi-
bition of T-cell proliferation mediated by B7-H1 was not
observed. However, both reports demonstrated B7-H1
expression in several leukemic cell lines. Our data support
the conclusion that B7-H1 expression upon AML at diag-
nosis is restricted; upon diagnosis, only 18% of patients
expressed B7-H1 in most cells.
B7-H1 is an inducible molecule; IFN-c, TNF-a and GM-
CSF can enhance B7-H1 expression under physiological
conditions [27–29]. Here, we conﬁrmed previous reports
showing that IFN-c induces B7-H1 in leukemic cell lines
[16, 26]. We previously demonstrated in the DA1-3b
mouse leukemic model that B7-H1 dose dependently
inhibits CTL [4]. Here, we observed that IFN-c induces and
enhances B7-H1 expression in most AML samples. Thus,
in addition to basal B7-H1 expression observed in some
patients, we hypothesize that IFN-c produced by T cells in
the AML microenvironment may induce T-cell inhibition
by inducing B7-H1 expression.
We also observed that TLR ligands induced B7-H1
expression in blast cells and increased resistance to CTLs.
B7-H1 expression induced by PGN, a TLR2 ligand, cor-
related positively with B7-H1 expression induced by LPS,
a TLR4 ligand, and by IFNc. AML blast cells that are
refractory to stimulation with one ligand are usually
refractory to others. Activation of TLR2, TLR4 and TLR9
induces B7-H1 in MM, leading to resistance to CTLs [13].
Activation of TLR4 on mouse tumor cells can also induce
B7-H1 expression, leading to immunoescape. TLR4 acti-
vation in Langerhans cells has recently been shown to
induce B7-H1 and favor tolerogenic properties in the oral
cavity [30, 31]. Until now, TLR expression in hematolog-
ical malignancies has been mostly reported in B-cell
tumors [32–38]. Data regarding TLR expression and
function in AML remain scarce. Numerous publications
have reported the possibility that AML blast cells differ-
entiate into leukemic dendritic cells (DC) using various
combinations of agents, including LPS [1, 15]. These
reports imply that AML blast cells may recognize LPS in
vitro when combined with cytokines, such as GM-CSF and
IL4. However, LPS can stimulate target cells through other
receptors besides the TLRs, and LPS alone is not sufﬁcient
to mature blast cells into dendritic cells. In the THP-1
leukemic cell line, induction of apoptosis by LPS plus
IFN-a has been reported, but primary AML samples
seemed less sensitive to this combination [39]. Altogether,
these experiments provide little information about the role
of TLRs in AML.
Recently, using gene expression proﬁling in a large
cohort of cytogenetically normal AMLs, Marcucci et al.
reported that TLR2, TLR4 and TLR8 expression was
inversely correlated with the levels of microRNA-181
family, and this correlation was associated with a worse
prognosis [40]. Here, we observed that TLR2, TLR4 and
TLR9 proteins were commonly expressed on AML blast
cells. Stimulation of TLR2 and TLR4 induced B7-H1
Fig. 3 T-cell inhibition by blast cells. a CTL activity of CD8-sorted
T cells expanded for 2 weeks against blast cells from six patients with
AML. Before the CTL assay, blast cells were pre-incubated for 1 h
with or without 500 ng/ml Ultrapure LPS, anti-B7-H1 mAb or isotype
control. Data represent the mean and SD of experiments performed in
quadruplicate. *indicates signiﬁcant differences with LPS (Student’s
t test). E:T effector:target ratio. b CTL activity of CD8-sorted T cells
expanded for 2 weeks against blast cells from one patient with AML
collected upon diagnosis and upon ﬁrst relapse. Target cells were pre-
incubated for 1 h with anti-B7-H1 or isotype control before the CTL
assay. Data represent the mean and SD of experiments performed in
quadruplicate
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These data indicate that receptors of innate immunity could
play a role in the development of AML.
A recent report studying gene expression proﬁles in
mouse hematopoietic stem cells during aging showed that
genes involved in inﬂammation and stress responses were
up-regulated in aged mice [41, 42], and Tlr4 was among
these genes. Thus, aging stem cells may be more sensitive
to inﬂammatory response. An attractive hypothesis is that
aging patients might be more prone to AML, in part
because their stem cells are more sensitive to stimulation
by TLR ligands, leading to immunoevasion of emerging
leukemic clones; but this hypothesis remains untested.
In some patients, blasts studied upon relapse showed
increased levels of B7-H1. This increase may have allowed
blasts to resist CTL-mediated killing, perhaps during the
complete remission period. However, given the low
number of paired samples analyzed during diagnosis and
relapse, further investigations using larger cohorts and on
blast cells isolated from minimal residual disease are
necessary to conﬁrm this hypothesis.
We also conﬁrmed that in leukemic cells, B7-H1
expression requires MEK, as previously shown in MM and
dermal ﬁbroblasts, and as recently conﬁrmed in bladder
carcinoma [13, 43, 44]. In addition to MAPK pathways,
PI3K/AKT plays a critical role in B7-H1 expression in
malignant gliomas, prostate and breast carcinoma, and
dermal ﬁbroblasts [19, 45]. We tested different inhibitors
of PI3K and mTOR and observed the effect on B7-H1
expression. We found no inhibition in leukemic cell lines
or in AML blast cells; rather, we found a slight enhance-
ment. This ﬁnding suggests that regulation of B7-H1
expression varies widely between cell types; thus, drugs
that target signal transduction pathways might have
Fig. 4 B7-H1 expression and
signal transduction inhibitors.
a B7-H1 mRNA levels (relative
to rRNA) in THP-1 (left panel)
and U937 (right panel) cells
measured by RQ-PCR following
24 h incubation with IFN-c with
or without 1-h pre-treatment
with signal transduction
inhibitors. Inhibitors included
the following: 20 lM UO126
(MEK1/2), 25 lM PD98059
(MEK1), 25 lM SP600125
(JNK), 25 lM AG490 (JAK2),
25 lM LY294002 (PI3K),
3 lM SB203850 (p38MAPK)
and 10 nM rapamycin (mTOR).
*indicates signiﬁcant
differences from cells treated
with IFN-c alone (Student’s
t test). b B7-H1 expression in 60
blast samples with or without
incubation with 25 lM of the
PI3K inhibitor LY294002.
c Same as in (b), but with
incubation with the mTOR
inhibitor rapamycin
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123different immunological effects in different tumors. MEK
inhibition not only inhibited B7-H1 expression, but also
sensitized blast cells expressing B7-H1 after stimulation
with LPS to CTL-mediated lysis. Current immunotherapy
strategies primarily use monoclonal antibodies or cell
therapy. Another approach would consist of using small,
targeted molecules to block immunoescape mechanisms
developed by cancer cells. MEK inhibitors could represent
a means to this end. Several of these molecules are cur-
rently under clinical development, including AZD6244.
These drugs have been developed to block tumor cell
proliferation or induce cell death by blocking growth and
survival signals, but our data show that they could also be
used to kill tumor cells indirectly via suppression of B7-H1
expression and CTL-mediated killing. We can also imagine
targeting B7-H1 via MEK after allogenic stem cell trans-
plantation to facilitate a graft-versus-leukemia effect, but
this strategy must be explored by further experiments.
Fig. 5 B7-H1 protein expression and MEK inhibitors. a Western blot
analysis of B7-H1 levels with anti-mouse B7-H1 mAb (clone 179711)
in DA1-3b mouse leukemic cells exposed to 500 IU/ml IFN-c with or
without 1-h pre-incubation with 20 lM UO126 (right panel)o r
25 lM rapamycin (left panel). b Western blot analysis of B7H1 levels
with anti-human B7-H1 mAb (clone 130002) in blast cells from one
patient with AML. Cells were exposed to 500 ng/ml Ultrapure LPS
for 24 h with or without pre-incubation with 20 lM UO126 or 1 lM
AZD6244. c Same as in (b), but in another AML patient and with
exposure to 500 IU/ml IFN-c instead of LPS
Fig. 6 CTL-mediated killing of blast cells and MEK inhibitors.
a CTL activity of CD8-sorted T cells expanded for 2 weeks against
blast cells from seven patients with AML; the cells were chosen for
their expression of B7-H1 after pre-incubation for 1 h with 500 ng/ml
Ultrapure LPS. Blast cells were exposed to 20 lM UO126 or 1 lM
AZD6244. Data represent the mean and SD of seven patients
performed in quadruplicate. *indicates signiﬁcant differences with
LPS (Student’s t test). b B7-H1 expression in blast cells from (a) after
exposure to LPS and 1 lM AZD6244. *indicates signiﬁcant differ-
ences between control and LPS; **indicates signiﬁcant differences
between LPS and LPS plus AZD6244 (Student’s t test). c B7-H1
expression in one representative sample from (b). d Same as in (a),
but with three patients who did not express B7-H1 after exposure to
LPS
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123In conclusion, we have identiﬁed B7-H1 as an immu-
noescape molecule in blast cells from patients with AML.
Expression of B7-H1 increases when these cells are
exposed to immune response, pathogens and sometimes
upon relapse, and increased expression may be targeted via
MEK inhibitors to facilitate CTL-mediated killing. These
ﬁndings suggest that B7-H1 may be a possible target for
immunotherapy via small molecules.
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